Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024

Published on March 28, 2024

This report describes the effectiveness of the updated COVID-19 vaccine in preventing hospitalizations in adults with immunocompromising conditions.

Continue reading on website
Other news

DR Congo mpox outbreak expands, becomes deadlier

March 25, 2024
DRC’s mpox outbreak has expanded to all but three of the country’s 26 provinces—and children are most affected, CIDRAP reports, citing a Friday WHO press briefing. The DRC has reported 3,941 suspected mpox cases this year—including 271 deaths.  Children account for two-thirds of the cases. The clade 1 virus behind the DRC outbreak is more virulent than the one circulating globally, with a case fat

Characterising the changes in RSV epidemiology in Beijing, China during 2015–2023: results from a prospective, multi-centre, hospital-based surveillance and serology study

April 1, 2024
Background: Respiratory syncytial virus (RSV) has posed substantial morbidity and mortality burden to young children and older adults globally. The coronavirus disease 2019 (COVID-19) pandemic was reported to have altered RSV epidemiology and could have important implications for RSV prevention and control strategies. We aimed to compare RSV epidemiology in different phases of the COVID-19 pandemi